拉帕替尼 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "拉帕替尼" in Chinese language version.

refsWebsite

Global rank Chinese rank

4^th place

5^th place

4web.archive.org

1^st place

1^st place

5^th place

12^th place

2^nd place

23^rd place

5,890^th place

228^th place

399^th place

208^th place

doi.org

Burris, Howard A. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist. 2004,. 9 Suppl 3 [2022-06-13]. ISSN 1083-7159. PMID 15163842. doi:10.1634/theoncologist.9-suppl_3-10. （原始内容存档于2022-06-15）.
Higa, Gerald M.; Abraham, Jame. Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy. 2007-09, 7 (9) [2022-06-13]. ISSN 1744-8328. PMID 17892419. doi:10.1586/14737140.7.9.1183. （原始内容存档于2022-06-13）.
Breast cancer drug approved for new indication. Women's Health (London, England). 2010-03, 6 (2) [2022-06-13]. ISSN 1745-5065. PMID 20187722. doi:10.2217/whe.10.11. （原始内容存档于2022-06-18）.

drugs.com

Lapatinib Uses, Side Effects & Warnings. Drugs.com. [2022-06-13]. （原始内容存档于2022-06-13）（英语）.

mnd.gov.tw

802.mnd.gov.tw

用藥指導 LAPATINIB^{[失效連結]}－國軍高雄總醫院

nih.gov

ncbi.nlm.nih.gov

Burris, Howard A. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist. 2004,. 9 Suppl 3 [2022-06-13]. ISSN 1083-7159. PMID 15163842. doi:10.1634/theoncologist.9-suppl_3-10. （原始内容存档于2022-06-15）.
Higa, Gerald M.; Abraham, Jame. Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy. 2007-09, 7 (9) [2022-06-13]. ISSN 1744-8328. PMID 17892419. doi:10.1586/14737140.7.9.1183. （原始内容存档于2022-06-13）.
Breast cancer drug approved for new indication. Women's Health (London, England). 2010-03, 6 (2) [2022-06-13]. ISSN 1745-5065. PMID 20187722. doi:10.2217/whe.10.11. （原始内容存档于2022-06-18）.

pubmed.ncbi.nlm.nih.gov

Burris, Howard A. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist. 2004,. 9 Suppl 3 [2022-06-13]. ISSN 1083-7159. PMID 15163842. doi:10.1634/theoncologist.9-suppl_3-10. （原始内容存档于2022-06-15）.
Higa, Gerald M.; Abraham, Jame. Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy. 2007-09, 7 (9) [2022-06-13]. ISSN 1744-8328. PMID 17892419. doi:10.1586/14737140.7.9.1183. （原始内容存档于2022-06-13）.
Breast cancer drug approved for new indication. Women's Health (London, England). 2010-03, 6 (2) [2022-06-13]. ISSN 1745-5065. PMID 20187722. doi:10.2217/whe.10.11. （原始内容存档于2022-06-18）.

web.archive.org

Burris, Howard A. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist. 2004,. 9 Suppl 3 [2022-06-13]. ISSN 1083-7159. PMID 15163842. doi:10.1634/theoncologist.9-suppl_3-10. （原始内容存档于2022-06-15）.
Higa, Gerald M.; Abraham, Jame. Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy. 2007-09, 7 (9) [2022-06-13]. ISSN 1744-8328. PMID 17892419. doi:10.1586/14737140.7.9.1183. （原始内容存档于2022-06-13）.
Breast cancer drug approved for new indication. Women's Health (London, England). 2010-03, 6 (2) [2022-06-13]. ISSN 1745-5065. PMID 20187722. doi:10.2217/whe.10.11. （原始内容存档于2022-06-18）.
Lapatinib Uses, Side Effects & Warnings. Drugs.com. [2022-06-13]. （原始内容存档于2022-06-13）（英语）.

worldcat.org

Burris, Howard A. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. The Oncologist. 2004,. 9 Suppl 3 [2022-06-13]. ISSN 1083-7159. PMID 15163842. doi:10.1634/theoncologist.9-suppl_3-10. （原始内容存档于2022-06-15）.
Higa, Gerald M.; Abraham, Jame. Lapatinib in the treatment of breast cancer. Expert Review of Anticancer Therapy. 2007-09, 7 (9) [2022-06-13]. ISSN 1744-8328. PMID 17892419. doi:10.1586/14737140.7.9.1183. （原始内容存档于2022-06-13）.
Breast cancer drug approved for new indication. Women's Health (London, England). 2010-03, 6 (2) [2022-06-13]. ISSN 1745-5065. PMID 20187722. doi:10.2217/whe.10.11. （原始内容存档于2022-06-18）.